Special Reports

Concert Pharma keeps it simple The science that Concert Pharmaceuticals is pursuing is the essence of simplicity. After spending years on the discovery side of the business, Roger Tung, PhD

What do you get when you make it to the top of Big Biotech's biggest companies? Millions in compensation, for one thing. But although the average pay for the CEOs listed is $14.42 million, most saw

New venture funds point Argos to a development crossroads Last week, Argos Therapeutics took a $35 million step toward its goal of generating proof-of-concept data. And after its first new venture

Aileron Therapeutics ramps up, aims big When Joseph A. Yanchik III started Aileron Therapeutics back in the middle of 2005, Apple Tree Partners came in and provided the seed money. He started with

Epix follows a new course in developing CF program For most investors, the sweet spot in any biotech play is right around proof-of-concept data on a new therapy for a disease that afflicts a large

Transave takes precise aim at lung infections Transave’s fortunes will rise or fall based on the success of its drug delivery technology. And with a fresh, $35 million venture round in its

Upstart Trius Therapeutics bolts ahead with fast-pace development plan When Jeff Stein, PhD, joined Sofinnova Ventures as a venture partner three years ago, he had already fleshed out the basic

2007 was a big year for Big Biotech, and while some of the top companies shined, other industry leaders took a beating. Biotech five biggest players--Amgen (1), Genentech (2), Biogen Idec (3),

Little Iomai comes up with a potentially big hit for bird flu In the scramble to come up with new vaccines that could protect populations from a potential human outbreak, scientists have frequently

Transition Therapeutics reaches a turning point  Nearly ten years after launching Transition Therapeutics, veteran entrepreneur and scientist Dr. Tony Cruz is under no illusions about his biotech

When we set out last week to identify the best-performing pharma stocks of 2007, we could resist scrolling to the bottom of the spreadsheet to

When it comes to picking stocks, prediction may be murky, but hindsight is crystal clear. We looked at every company in the Wall Street Journal's pharma sector (plus a few others of our own

Take a look at FiercePharma's 2007 year-end round-up and our predictions for the year ahead.   2007 pharma industry trends: 1.

Since FiercePharma was launched in August we’ve published hundreds of articles, but there are some that are clear favorites with our readers. Check out this list of our most-read articles in 2007

2007 was a year of high-profile drug safety warnings. Check out this report for a look at the 10 biggest drugs--ranked by 2006 sales--that drew new, FDA-issued warnings or withdrawals. 

2007 has been a year of high-profile drug safety warnings. Check out this report for a look at the 10 biggest drugs with new, FDA-issued warnings or withdrawals this year. The drugs are ranked by

Count GlaxoSmithKline's Puerto Rican plant as an early Avandia casualty. The drug maker will close the factory in Cidra, Puerto Rico, and transfer production of the diabetes med (and its cousin